Eisai inks Latin America deal for obesity drug

16 October 2018

Japanese pharma major Eisai (TYO: 4523) has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratórios, which has a business foundation in Latin America.

Under this agreement, Eisai will supply Eurofarma with lorcaserin, which is marketed in the USA and some other countries as Belviq.

Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country. Eisai’s shares were lifted 1.55% to 10,460 yen on the news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK